BioNTech is a German biotechnology company founded in 2008, known for its focus on the development of immunotherapies for cancer as well as infectious diseases, including the COVID-19 vaccine. The company gained widespread recognition for its collaboration with Pfizer to create one of the first effective mRNA vaccines, BNT162b2, to combat COVID-19. BioNTech’s proprietary platform utilizes messenger RNA (mRNA) technology to instruct cells in the body to produce proteins that can trigger an immune response. This innovative approach has implications not only for vaccine development but also for personalized cancer treatments and other therapeutic areas. BioNTech is headquartered in Mainz, Germany, and has established itself as a key player in the biopharmaceutical industry.
BioNTech, known for its Covid-19 vaccine, is transitioning towards mRNA-based cancer therapies aiming for market approval by 2026. The company's earnings per share fell to €1.08, surpassing market forecasts, while…